Biodesix (BDSX) Corporate presentation summary

Mission and vision

• Aims to transform patient care and improve outcomes through timely, accessible, personalized diagnostics addressing immediate clinical needs.

• Envisions conquering diseases with the guidance of personalized diagnostics.

Business model and revenue streams

• Generates revenue from two business lines: lung diagnostic tests and development services for biopharma, life sciences, and academic partners.

• Focuses on supporting clinical decisions in lung disease and enabling partners with scientific and operational capabilities.

Financial performance and growth

• FY 2026 revenue guidance increased to $108–114M, representing 25% growth over 2025.

• Q1 2026 revenues reached $25.6M, with 42% YoY growth and industry-leading 82% gross margins.

• Adjusted EBITDA improved by 35% from Q1 2025.